Inogen (INGN) Aandeel Koers
Inogen Koers
In de afgelopen 14 jaar liet Inogen de omzet jaarlijks met 19,0% groeien tot 348,67 Miljoen USD. De winst per aandeel is de afgelopen 7 jaar met 58,1% per jaar gegroeid. Bij Inogen is de nettowinstmarge met -6,5% ten opzichte van -1,8% enkele jaren geleden gedaald. Het consensus-koersdoel voor Inogen op 12 maanden bedraagt 26,00 USD, circa 287,5% boven de huidige koers. Van de 8 analisten geven 7 het aandeel een koopadvies — per saldo een Kopen-consensus.
Inogen aandeelkoers
Deze data ophalen via de Eulerpool API
100.000 requests/maand gratis · geen creditcard
Inogen bedrijfsmodel & aandelenanalyse
Veelgestelde vragen over Inogen
The business model of Inogen Inc is centered around developing and manufacturing innovative medical devices for the oxygen therapy market. Inogen primarily focuses on designing portable oxygen concentrators (POCs) that can enhance the quality of life for individuals requiring oxygen therapy. Inogen's POCs offer flexibility, mobility, and convenience, enabling patients to engage in various activities while receiving the necessary oxygen support. By providing technologically advanced and user-friendly solutions, Inogen aims to improve patient outcomes and enable individuals with respiratory conditions to lead active and independent lives. Inogen Inc is committed to meeting the evolving needs of the oxygen therapy industry by continuously developing and enhancing its product portfolio.
Inogen Inc is primarily active in the medical device industry.
The main competitors of Inogen Inc in the market are Philips Respironics and Invacare Corporation.
Inogen Inc is a renowned medical technology company specializing in the development and manufacture of portable oxygen concentrators. Founded in 2001 and based in Goleta, California, Inogen has revolutionized the industry by providing innovative and efficient oxygen therapy solutions to patients worldwide. With a strong commitment to enhancing the quality of life for those with respiratory conditions, Inogen has built a solid reputation for its cutting-edge products and exceptional customer service. The company's dedication to research, design, and manufacturing excellence has positioned it as a global leader in the oxygen therapy market, ensuring a brighter and healthier future for individuals in need of respiratory support.
Inogen Inc has achieved several significant milestones over the years. One notable achievement is the development of portable oxygen concentrators, revolutionizing the way individuals with respiratory conditions receive oxygen therapy. In 2008, the company received FDA approval for the Inogen One, its first breakthrough product. Inogen Inc has also expanded its operations globally, catering to a wider customer base across different countries. Furthermore, the company has consistently been recognized for its innovation and contributions to the medical industry. These milestones collectively highlight Inogen Inc's commitment to providing high-quality, life-enhancing solutions for individuals with respiratory needs.
Inogen Inc is primarily present in numerous countries and regions worldwide. With its focus on providing innovative and portable oxygen concentrators, Inogen has established a strong presence in various markets. The company's products and services are available across North America, including the United States and Canada, where it has a significant customer base. In addition, Inogen Inc has expanded its operations to international markets, including Europe, Australia, and Asia. Through its global distribution network and partnerships, Inogen continues to reach and serve customers in diverse geographical locations.
Inogen Inc represents values of innovation, quality, and compassion in providing portable oxygen concentrators and respiratory products. With a corporate philosophy focused on improving the quality of life for individuals with respiratory conditions, Inogen strives to enhance mobility, independence, and freedom for patients worldwide. The company's commitment to developing reliable and efficient solutions is evident through its dedication to research and development, customer service, and manufacturing excellence. Inogen Inc exemplifies its core values by providing market-leading products and exceptional support for patients to maintain an active and fulfilling lifestyle.
Analisten hanteren momenteel een gemiddeld koersdoel van 26,00 USD voor het aandeel Inogen (mediaan: 26,00 USD), oftewel +287,5 % ten opzichte van de laatste koers. De consensus is gebaseerd op 8 analistenratings.
8 analisten beoordelen het aandeel Inogen momenteel: 7 adviseren kopen, 1 houden en 0 verkopen. Voor 2026 verwachten analisten dat Inogen een omzet van 356,42 Miljoen USD en winst per aandeel van -0,75 USD behaalt.
Omgezet tegen de huidige wisselkoers noteert het aandeel Inogen op 5,98 EUR (6,71 USD).
Het aandeel Inogen (INGN) is genoteerd aan 4 beurzen, waaronder: NASDAQ (INGN), SIX (Zürich) (6IO.SW), Frankfurt (6IO.F), Düsseldorf (6IO.DU).
Inogen Inc. is a leading health company specializing in the development, manufacturing, and distribution of respiratory therapy devices. The company's main business is the production of portable oxygen concentrators which can improve the quality of life for patients with health issues. The products offered by Inogen are innovative, space-saving, and lightweight oxygen therapy devices that allow patients to maintain their breathing during daily life activities and have more freedom and independence. These devices are usually smaller and lighter than traditional oxygen systems and designed for easy transportation and operation by patients. Inogen has three main product lines: the Inogen One G5 portable oxygen concentrator, the Inogen at Home electric oxygen concentrator, and the Inogen One G4 portable oxygen concentrator. The Inogen One G5 is a portable oxygen concentrator that offers long battery life and convenient mobility. The Inogen at Home electric oxygen concentrator is a stationary system that provides continuous oxygen supply in the private home environment. The Inogen One G4 is a portable oxygen concentrator that is even smaller and lighter than the Inogen One G5. Inogen also offers accessories for the devices including additional batteries, carrying backpacks, nasal cannulas, and other replacement parts. The company sells its products in the USA and over 30 other countries worldwide. Another business segment of Inogen is the sale of devices to third-party providers including hospitals, doctors, and other healthcare professionals. Inogen provides a comprehensive range of services including service guides, installation, and customer support. Inogen has achieved success due to its technological innovation, high product quality, and customer focus. The company engages in intensive marketing to increase brand awareness and product visibility. Inogen has successful and trained team members in sales, consultation, customer care, and technical support who meet the needs of customers. Inogen follows a co-marketing model that allows them to collaborate with other healthcare partners. These partnerships help the company present its products to a wider customer segment and develop potential business opportunities. As a socially responsible company, Inogen collaborates with various non-profit organizations to achieve its goal of improving the quality of life for patients with respiratory issues. Inogen also strives to act in an environmentally conscious manner and ensures that its devices are environmentally friendly. For example, the devices' batteries are rechargeable and the materials and components are easily reusable. Overall, Inogen's business model focuses on technological innovation, customer orientation, and social responsibility. The company utilizes its core competencies and dedicated employees to create top-notch products and provide high-quality customer service. Inogen is a sound company with robust growth potential and is well-positioned to maintain its market leadership in respiratory therapy.
De verwachte omzet van Inogen bedraagt 356,42 Miljoen USD. Deze cijfers zijn gebaseerd op huidige financiële gegevens en weerspiegelen de bedrijfsresultaten van het bedrijf.
De verwachte winst van Inogen bedraagt -20,32 Miljoen USD. De nettowinst weerspiegelt de rentabiliteit van het bedrijf na aftrek van alle kosten.
De koers-winstverhouding (P/E) van Inogen bedraagt momenteel -8,97. De P/E-ratio vergelijkt de huidige aandeelkoers met de winst per aandeel en helpt beleggers de waardering van het Inogen-aandeel in te schatten.
De koers-omzetverhouding (P/S) van Inogen bedraagt momenteel 0,51. De P/S-ratio vergelijkt de marktkapitalisatie met de jaarlijkse opbrengsten en dient als waarderingsmaatstaf voor het Inogen-aandeel.
De Eulerpool Kwaliteitsscore voor Inogen is 1/10.
De ISIN van Inogen is US45780L1044. De ISIN (International Securities Identification Number) is een wereldwijd unieke identificatie voor wertpapieren.
De WKN van Inogen is A1XB32. De WKN (Wertpapierkennnummer) is een zescijferig Duits identificatienummer voor wertpapieren.
Het tickersymbool van Inogen is INGN. Onder dit beurstickersymbool wordt het Inogen-aandeel op de beurs verhandeld.
Inogen aandeel
Inogen Peer Group
Inogen Ticker
Inogen FIGI
Alle fundamentals en diepgaande analyse van Inogen
Onze aandelenanalyse van het Inogen-aandeel omvat belangrijke financiële kerncijfers zoals de omzet, de winst, de P/E-ratio, de P/S-ratio, de EBIT, evenals informatie over het dividend. Daarnaast bekijken we aspecten zoals aandelen, marktkapitalisatie, schulden, eigen vermogen en verplichtingen van Inogen. Als u meer gedetailleerde informatie zoekt over deze onderwerpen, bieden we op onze subpagina's uitgebreide analyses: